- Home
- CINT vs MGTX Comparison
CINT vs MGTX Comparison
Compare CINT & MGTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | CINT | MGTX |
|---|---|---|
| Founded | 1995 | 2015 |
| Country | Brazil | United States |
| Employees | N/A | N/A |
| Industry | EDP Services | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 566.6M | 579.5M |
| IPO Year | 2021 | N/A |
Fundamental Metrics
Financial Performance| Metric | CINT | MGTX |
|---|---|---|
| Price | $4.95 | $7.45 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 5 | 6 |
| Target Price | $7.00 | ★ $23.83 |
| AVG Volume (30 Days) | 193.6K | ★ 400.1K |
| Earning Date | 03-11-2026 | 03-12-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 46.10 | N/A |
| EPS | ★ 0.27 | N/A |
| Revenue | ★ $467,906,000.00 | $27,417,000.00 |
| Revenue This Year | $13.00 | N/A |
| Revenue Next Year | $12.62 | $569.48 |
| P/E Ratio | $18.16 | ★ N/A |
| Revenue Growth | 1.90 | ★ 96.83 |
| 52 Week Low | $3.98 | $4.55 |
| 52 Week High | $7.50 | $9.73 |
Technical Indicators
Market Signals| Indicator | CINT | MGTX |
|---|---|---|
| Relative Strength Index (RSI) | 52.95 | 49.04 |
| Support Level | $4.84 | $7.16 |
| Resistance Level | $5.16 | $7.64 |
| Average True Range (ATR) | 0.23 | 0.39 |
| MACD | -0.02 | -0.01 |
| Stochastic Oscillator | 24.53 | 43.41 |
Price Performance
Historical ComparisonAbout CINT CI&T Inc
CI&T Inc is engaged in providing plans, design, and software engineering services to enable digital transformation for companies. The company mainly develops customizable software through the implementation of several software solutions, including Machine Learning, Artificial Intelligence (AI), Analytics, Cloud, and Mobility technologies. The majority of the revenue is generated from the North America and Europe, followed by Asia, Pacific and Japan.
About MGTX MeiraGTx Holdings plc
MeiraGTx Holdings PLC is a clinical-stage gene therapy company. It focuses on the eye, salivary gland, and central nervous system disorders. The company's pipeline products include AAV-CNGB3, AAV-CNGA3 and AAV-RPGR, and others. Geographically, it operates in the United States, the United Kingdom, and European Union.